Company Filing History:
Years Active: 2008
Title: Pedro López Saura: Innovator in Genetic Engineering
Introduction
Pedro López Saura is a notable inventor based in La Habana, Cuba. He has made significant contributions to the field of genetic engineering and biotechnology. His work focuses on developing innovative solutions for various medical challenges.
Latest Patents
Pedro López Saura holds a patent for a groundbreaking invention titled "Chimeric antagonist anth1." This recombinant chimeric antagonist is formed by a 60 amino acid fragment of the N-terminal region of human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha subunit of the gamma IFN (IFN γ) receptor. In vitro, this protein exhibits T cell growth-stimulating activity while inhibiting the growth-stimulating activity of IL-2 in T cells. Additionally, it inhibits the induction of HLA-DR by IFN γ and the antiproliferative activity of γ IFN. This invention has potential applications in medicine for treating several pathologies, including autoimmune diseases, graft rejections, chronic inflammations, sepsis, ischemia and reperfusion syndrome, and atherosclerosis. He has 1 patent to his name.
Career Highlights
Pedro López Saura is affiliated with the Centro de Ingeniería Genética y Biotecnología, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on medical treatments and therapies.
Collaborations
He has collaborated with notable colleagues, including Iraldo Bello Rivero and Yeny Torres Ruiz, contributing to a dynamic research environment that fosters innovation.
Conclusion
Pedro López Saura is a distinguished inventor whose work in genetic engineering holds promise for addressing critical medical issues. His contributions to the field exemplify the importance of innovation in improving healthcare outcomes.